For research use only. Not for therapeutic Use.
HDAC inhibitor that shows marked cytotoxicity and induces apoptosis as well as cell cycle arrest in a panel of breast cancer cell lines. LW479 silences EGFR expression in breast cancer cells through disrupting Sp1 and HDAC1 binding to EGFR promoter, and blocks EGF/EGFR signalling pathway and EGF-stimulated motility. Moreover, LW-479 attenuates breast cancer metastasis to the lung.
| Catalog Number | I047610 |
| CAS Number | 1688677-89-5 |
| Molecular Formula | C21H23BrN2O4S |
| Purity | ≥95% |
| IUPAC Name | 6-[2-[2-(3-bromophenyl)-4-oxo-1,3-thiazolidin-3-yl]phenoxy]-N-hydroxyhexanamide |
| InChI | InChI=1S/C21H23BrN2O4S/c22-16-8-6-7-15(13-16)21-24(20(26)14-29-21)17-9-3-4-10-18(17)28-12-5-1-2-11-19(25)23-27/h3-4,6-10,13,21,27H,1-2,5,11-12,14H2,(H,23,25) |
| SMILES | C1C(=O)N(C(S1)C2=CC(=CC=C2)Br)C3=CC=CC=C3OCCCCCC(=O)NO |
| Reference | J. Li et al. Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression. Br J Pharmacol. 2015 Aug;172(15):3817-30. |
